Solve Therapeutics
Targeting cancer with best-in-class ADCs
Belmont, United States · Founded 2021 · $321.0M raised
- Headquarters
- Belmont, California
- Employees
- 11–50
- Founded
- 2021
- Business Model
- B2B
- Website
- solvetherapeutics.com
- Total Funding
- $321.0M
- Last Round
- $120.0M Series BNov 2025
- Rounds
- 3
About
Solve Therapeutics is a clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) and bispecific therapeutics targeting cancer. The company focuses on high selectivity and optimized payload delivery to improve outcomes for patients with solid tumors.
Summary
Solve Therapeutics is a Life Sciences company based in Belmont, United States, founded in 2021. It has raised $321.0M in total across 3 rounds, most recently a $120.0M Series B round in Nov 2025. Investors include Yosemite, OrbiMed and Ally Bridge Group.
Tech & App Stack
2 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Nov 2025
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...